Pipernonaline exhibits anti-prostate cancer activity by inhibiting the proliferation of both androgen-dependent and androgen-independent LNCaP/PC-3 prostate cancer cells; it activates caspase-3, promotes cleavage of procaspase-3 and PARP, and mediates reactive oxygen species (ROS) production, intracellular Ca²⁺ elevation, and mitochondrial membrane depolarization.